🔗 Share this article

While America proceeds with unprecedented revisions to its vaccine recommendations, one figure has emerged somewhat surprisingly: Tracy Beth Høeg, a Danish American physician and public health researcher who first made her name by expressing skepticism about coronavirus vaccinations throughout the pandemic and has focused upon possible deaths after COVID-19 vaccination in her short time at the Food and Drug Administration.

Planned Overhauls to Childhood Immunization Program

Health officials were set to announce radical changes to the childhood vaccination calendar in December, aligning the US with Denmark’s vaccine program, it is understood – a major change that would place the US out of alignment with many the global community with no evidence for benefit. The planned update has been delayed until the coming year.

Rather than the top vaccines chief, Dr. Høeg is listed to speak at the gathering. She was just designated interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to lead the center this calendar year.

Consolidating Power at the Regulatory Body

The acting appointment could signify a closer partnership between the pharmaceutical and vaccine branches as Dr. Høeg and Dr. Prasad solidify control at the FDA – and it points to a greater focus upon dismantling already-approved vaccines at the FDA.

Høeg has often pushed for ending specific childhood vaccine recommendations in the US in order to be more in line with Denmark, a country with nationalized medicine and a number of inhabitants approximately the size of Wisconsin’s.

In her initial statements, she has continued to focus on immunizations – typically the domain of Dr. Prasad, director of the FDA’s CBER – instead of medication approval.

Doubts Over Background

The appointee has no obvious background in drug development, oversight or administrative roles, which has been customary for past directors of the CBER. She has served at the FDA as a senior adviser to the FDA chief and the vaccine center since earlier this year.

“She appears not to have any of the qualifications” for overseeing the drug-regulation department, remarked Dr. Jonathan Howard. “She’s never run a scientific study. She has no expertise in leading a sizeable institution. She is not an expert in industry regulation.”

Previous directors of the center would “grasp legal statutes and the underlying principles of pharmaceutical innovation”, commented Dr. Janet Woodcock. “Frankly, she has not acquired the type of experience that previous people who headed the center have had.”

The drug center has an vast portfolio at the FDA, Woodcock emphasized.

“The public just pays attention on the new drug program, but the generic program clears a multitude of generic medications. There’s a biosimilars program, OTC medication office and more, and each of these must be looked after,” Dr. Woodcock said. “The area you neglect, that is precisely what that I always told people is going to come back to haunt you.”

Furthermore, a significant administrative aspect to the position, which supervises in excess of 5,000 personnel. “It is a massive management job, if you execute it properly,” the former official concluded.

Agency Reaction and Contentious Policies

Regarding inquiries about Høeg’s fitness for the role and whether this assignment indicates increased cooperation among FDA leaders on immunizations, a press secretary responded that the “questions are based on incorrect premises”.

“This background aligns with the responsibilities of her position,” the spokesperson stated, noting the time Dr. Høeg spent guiding the FDA commissioner on “pharmaceutical safety and approval science, including predictive safety algorithms and vaccine surveillance”.

As acting director, Høeg inherits the commissioner’s controversial priority voucher program, a disputed expedited medication authorization process that reportedly concerned her preceding directors. “By what process are these medications being picked for this fast-track system? Who is making the choices?” Howard questioned. “There’s a lot of secrecy occurring at the agency right now.”

Broadly speaking, he stated, “the FDA appears to be shifting towards laxer oversight of pharmaceuticals, except for shots.”

Documented History on Immunizations

Concerning vaccines, Høeg has a more documented, if troubling, history, Howard said. She released a analysis using unconfirmed volunteer-provided data to determine the rate of heart inflammation following COVID-19 vaccination. She advised the Florida top health official Joseph Ladapo, who allegedly have modified findings to indicate Covid vaccines are more dangerous than they are.

Included in her “policy goals” for the current administration featured changing regulations for recently developed shots and halting “unnecessary” vaccines, she stated post-election on a online show. At the agency, Dr. Høeg has allegedly floated the idea of preventing teenage boys from getting COVID-19 vaccines.

“She’s an all-around dogmatist who starts off with her conclusions and works backwards to fit the data in a very deceptive, untruthful way,” Howard argued.

Gaining Influence and a “Campaign of Retribution”

Dr. Høeg aligned with other skeptics, {like|